Osaka University Venture Capital

Founded in Japan in 2017, Luxna Biotech specializes in developing nucleic acid drugs using advanced artificial technology. The company focuses on creating safe and effective oligonucleotide therapeutics based on licensed cross-linked modified nucleic acid groups.

SK Fine specializes in advanced ceramics manufacturing. It pioneered Japan's first commercial 3D printer for ceramics and offers custom 3D ceramic parts based on client-provided CAD data.

Founded in 2018, Aipore specializes in developing nanopore sensors using semiconductor Si microfabrication technology. These sensors measure and analyze changes in ion current flow, enabling accurate identification of particles such as viruses for diverse industrial applications like microbiological testing, cancer detection, and environmental evaluation.

GlyTech specializes in the production of human-type N-glycans and chemical glycosylation technologies. It offers custom synthesis services, contract manufacturing, and licenses its products for use in biopharmaceuticals and oligonucleotide therapeutics.

PGV Co., Ltd., founded in September 2016 and based in Japan, specializes in the development of electroencephalogram (EEG) related technologies. The company focuses on creating innovative brain wave sensor devices, specifically patch-type electroencephalographs, which allow for the accurate measurement of brain waves in a manner similar to using a thermometer. By integrating artificial intelligence for data analysis, PGV aims to facilitate self-care through the continuous monitoring of brain activity, thereby enhancing personal health management. The company's advancements are designed to support medical professionals in delivering efficient and effective patient care through accurate data collection and machine learning applications.

Kringle Pharma is a Japanese biopharmaceutical company focused on the research and development of hepatocyte growth factor (HGF)–based protein medicines and NK4 therapies. The company aims to leverage HGF’s regenerative properties and NK4’s antiangiogenic activity to address organ repair and cancer indications. Its pipeline includes recombinant human HGF for acute renal failure, spinal cord injury, and CNS diseases, as well as recombinant NK4 and NK4 gene therapies for cancer. Founded in 2001, the company operates in the Japanese market.

Founded in Japan in 2017, Luxna Biotech specializes in developing nucleic acid drugs using advanced artificial technology. The company focuses on creating safe and effective oligonucleotide therapeutics based on licensed cross-linked modified nucleic acid groups.

PGV Co., Ltd., founded in September 2016 and based in Japan, specializes in the development of electroencephalogram (EEG) related technologies. The company focuses on creating innovative brain wave sensor devices, specifically patch-type electroencephalographs, which allow for the accurate measurement of brain waves in a manner similar to using a thermometer. By integrating artificial intelligence for data analysis, PGV aims to facilitate self-care through the continuous monitoring of brain activity, thereby enhancing personal health management. The company's advancements are designed to support medical professionals in delivering efficient and effective patient care through accurate data collection and machine learning applications.

Founded in Japan in 2017, Remohab specializes in remote telemedicine solutions for rehabilitation patients. Its core product, the Remohub system, leverages IoT and ICT technologies to connect patients at home with medical institutions remotely, facilitating cardiac rehabilitation.

Cykinso, Inc., founded in 2014 and based in Kawasaki-Shi, Japan, specializes in developing and selling direct-to-consumer microbiome testing kits. The company offers a home-testing solution that assesses the state of an individual's intestinal bacteria. Utilizing advanced sequencing technology, Cykinso's kit rapidly analyzes a vast number of DNA sequences to provide users with insights into their gut health. This information helps individuals understand the relationship between their intestinal flora and various lifestyle-related and digestive diseases, enabling them to make informed health decisions based on their gut microbiome data.

Founded in 2016, MiCAN Technologies specializes in producing and supplying homogeneous blood cells using regenerative medicine technology. These cells facilitate drug safety evaluation, functional material research, and infectious disease studies, with a focus on malaria.

C4U Co., Ltd. is a life science start-up based in Suita, Japan, specializing in the research and development of advanced genome editing technologies. Founded in 2018, the company focuses on utilizing CRISPR and Cas3 methods to create innovative tools for drug discovery and therapeutic applications. C4U aims to address various intractable diseases and contribute to solutions for pressing social issues across multiple sectors, including medicine, agriculture, forestry, livestock, and fisheries. By developing a robust platform for gene editing, C4U supports pharmaceutical companies in their quest for new gene therapy methods and enhances the potential for groundbreaking advancements in healthcare and beyond.

SK Fine specializes in advanced ceramics manufacturing. It pioneered Japan's first commercial 3D printer for ceramics and offers custom 3D ceramic parts based on client-provided CAD data.

Founded in 2018, Aipore specializes in developing nanopore sensors using semiconductor Si microfabrication technology. These sensors measure and analyze changes in ion current flow, enabling accurate identification of particles such as viruses for diverse industrial applications like microbiological testing, cancer detection, and environmental evaluation.

C4U Co., Ltd. is a life science start-up based in Suita, Japan, specializing in the research and development of advanced genome editing technologies. Founded in 2018, the company focuses on utilizing CRISPR and Cas3 methods to create innovative tools for drug discovery and therapeutic applications. C4U aims to address various intractable diseases and contribute to solutions for pressing social issues across multiple sectors, including medicine, agriculture, forestry, livestock, and fisheries. By developing a robust platform for gene editing, C4U supports pharmaceutical companies in their quest for new gene therapy methods and enhances the potential for groundbreaking advancements in healthcare and beyond.

Chromocenter Inc. is a biopharmaceutical company based in Yonago, Japan, established in 2005. The company specializes in developing artificial chromosome technologies, primarily focusing on applications within the life sciences sector. Chromocenter's innovative approach utilizes artificial chromosome vectors to facilitate drug discovery and the construction of stable gene expression cell lines, which are essential for high protein production. Additionally, the company offers services such as chromosome analysis and various forms of fluorescence in situ hybridization (FISH), including multicolor and monochrome analysis. Through its advanced technologies, Chromocenter aims to provide clinicians with safe and effective pharmaceuticals for treating a range of diseases.

Chromocenter Inc. is a biopharmaceutical company based in Yonago, Japan, established in 2005. The company specializes in developing artificial chromosome technologies, primarily focusing on applications within the life sciences sector. Chromocenter's innovative approach utilizes artificial chromosome vectors to facilitate drug discovery and the construction of stable gene expression cell lines, which are essential for high protein production. Additionally, the company offers services such as chromosome analysis and various forms of fluorescence in situ hybridization (FISH), including multicolor and monochrome analysis. Through its advanced technologies, Chromocenter aims to provide clinicians with safe and effective pharmaceuticals for treating a range of diseases.

Jeplan, Inc. is a Japanese company specializing in recycling technologies and systems aimed at promoting sustainable practices. Founded in January 2007 and based in Tokyo, it develops innovative solutions that cater to diverse consumer needs. The company utilizes proprietary chemical recycling technology to transform waste materials, such as food packaging and plastic PET bottles, into recycled polyethylene terephthalate (r-PET) resin and Bis(2-Hydroxyethyl) terephthalate (r-BHET) resin. These recycled materials are then used in the manufacturing of various products, including PET bottles and textiles. In addition to its technological advancements, Jeplan is involved in promoting the recycling of used uniforms and offers consulting services to businesses looking to implement recycling initiatives. Through its efforts, Jeplan aims to enhance recycling efficiency and contribute to environmental sustainability.

GlyTech specializes in the production of human-type N-glycans and chemical glycosylation technologies. It offers custom synthesis services, contract manufacturing, and licenses its products for use in biopharmaceuticals and oligonucleotide therapeutics.

Founded in Japan in 2017, Luxna Biotech specializes in developing nucleic acid drugs using advanced artificial technology. The company focuses on creating safe and effective oligonucleotide therapeutics based on licensed cross-linked modified nucleic acid groups.

Pi-Crystal Incorporation, founded in 2013 and headquartered in Osaka, Japan, specializes in the development and manufacture of printable organic semiconductor integrated circuits. The company focuses on research and development, design, and sales of organic semiconductor materials and devices, utilizing innovative technologies that differ significantly from traditional silicon semiconductors. Its products are designed for flexibility and low-cost production, making them suitable for various industrial applications. By leveraging unique materials and film formation methods, Pi-Crystal enables clients to create soft, thin, lightweight, and inexpensive devices, contributing to advancements in the Internet of Things sector.

PGV Co., Ltd., founded in September 2016 and based in Japan, specializes in the development of electroencephalogram (EEG) related technologies. The company focuses on creating innovative brain wave sensor devices, specifically patch-type electroencephalographs, which allow for the accurate measurement of brain waves in a manner similar to using a thermometer. By integrating artificial intelligence for data analysis, PGV aims to facilitate self-care through the continuous monitoring of brain activity, thereby enhancing personal health management. The company's advancements are designed to support medical professionals in delivering efficient and effective patient care through accurate data collection and machine learning applications.

Founded in Japan in 2017, Remohab specializes in remote telemedicine solutions for rehabilitation patients. Its core product, the Remohub system, leverages IoT and ICT technologies to connect patients at home with medical institutions remotely, facilitating cardiac rehabilitation.

KOTAI Biotechnologies, Inc. is a biotechnology company based in Osaka, Japan, specializing in the development of a structural modeling and analysis platform for immune cell receptors. The company's innovative technology enables the extraction of detailed structural and functional information from immune cell sequences derived from routine blood samples. This capability has significant implications for understanding resistance to infections, autoimmune diseases, and cancer. KOTAI collaborates with academic institutions and pharmaceutical companies to advance research and development, focusing on the creation of diagnostic and therapeutic methods. Their platform, known as Repertoire Builder, organizes immune receptors based on their target epitopes, utilizing sequence and structural features from B and T cell receptor models. This functionality helps delineate the functional landscape of individual donors and quantifies variations between different individuals, ultimately supporting drug discovery and improving diagnostic and prognostic capabilities.

KOTAI Biotechnologies, Inc. is a biotechnology company based in Osaka, Japan, specializing in the development of a structural modeling and analysis platform for immune cell receptors. The company's innovative technology enables the extraction of detailed structural and functional information from immune cell sequences derived from routine blood samples. This capability has significant implications for understanding resistance to infections, autoimmune diseases, and cancer. KOTAI collaborates with academic institutions and pharmaceutical companies to advance research and development, focusing on the creation of diagnostic and therapeutic methods. Their platform, known as Repertoire Builder, organizes immune receptors based on their target epitopes, utilizing sequence and structural features from B and T cell receptor models. This functionality helps delineate the functional landscape of individual donors and quantifies variations between different individuals, ultimately supporting drug discovery and improving diagnostic and prognostic capabilities.

PGV Co., Ltd., founded in September 2016 and based in Japan, specializes in the development of electroencephalogram (EEG) related technologies. The company focuses on creating innovative brain wave sensor devices, specifically patch-type electroencephalographs, which allow for the accurate measurement of brain waves in a manner similar to using a thermometer. By integrating artificial intelligence for data analysis, PGV aims to facilitate self-care through the continuous monitoring of brain activity, thereby enhancing personal health management. The company's advancements are designed to support medical professionals in delivering efficient and effective patient care through accurate data collection and machine learning applications.

KOTAI Biotechnologies, Inc. is a biotechnology company based in Osaka, Japan, specializing in the development of a structural modeling and analysis platform for immune cell receptors. The company's innovative technology enables the extraction of detailed structural and functional information from immune cell sequences derived from routine blood samples. This capability has significant implications for understanding resistance to infections, autoimmune diseases, and cancer. KOTAI collaborates with academic institutions and pharmaceutical companies to advance research and development, focusing on the creation of diagnostic and therapeutic methods. Their platform, known as Repertoire Builder, organizes immune receptors based on their target epitopes, utilizing sequence and structural features from B and T cell receptor models. This functionality helps delineate the functional landscape of individual donors and quantifies variations between different individuals, ultimately supporting drug discovery and improving diagnostic and prognostic capabilities.

Chromocenter Inc. is a biopharmaceutical company based in Yonago, Japan, established in 2005. The company specializes in developing artificial chromosome technologies, primarily focusing on applications within the life sciences sector. Chromocenter's innovative approach utilizes artificial chromosome vectors to facilitate drug discovery and the construction of stable gene expression cell lines, which are essential for high protein production. Additionally, the company offers services such as chromosome analysis and various forms of fluorescence in situ hybridization (FISH), including multicolor and monochrome analysis. Through its advanced technologies, Chromocenter aims to provide clinicians with safe and effective pharmaceuticals for treating a range of diseases.

Matrixome Inc is a scientific research company based in Osaka, Japan, dedicated to the research and development of protein-based pharmaceutical preparations. Incorporated in 2015, the company focuses on the study of matrixosomes, a concept introduced by Professor Kiyotoshi Sekiguchi, which emphasizes the interactions between cells and their extracellular environment. Matrixome's product offerings include iMAtrix-221, a substrate designed for the purification and maintenance of cardiomyocytes; iMatrix-441, which induces endothelial progenitor cells for induced pluripotent stem cells; and iMatrix-511, a recombinant human laminin-511 E8 fragment intended for use in cell culture. Through its innovative research, Matrixome aims to provide valuable insights for biotechnology researchers and advance the field of regenerative medicine.

Founded in 1993, JTEC specializes in designing, manufacturing, and selling X-ray mirrors for synchrotron facilities, enabling research across various fields. The company also develops automated cell culture systems and other automated solutions.